In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Medical Device

The Making Of A CEO: Robert Greenberg, MD

Executive Summary

Robert Greenberg, MD, hadn’t served as a CEO prior to taking the post at Second Sight, didn’t even post any significant executive experience. But he did have some success as an entrepreneur prior to joining the company.

You may also be interested in...



Glaukos Holds Lead In Microinvasive Glaucoma Surgery

Glaukos has emerged as the leader in microinvasive glaucoma surgery, a new treatment for the multibillion-dollar market. CEO Tom Burns lays out his vision for his company and for the future of MIGS.

Finding The Fit For Ophthalmology In The New Pfizer

The merger of Pfizer and Allergan might raise broader questions about the fairness – or long-term viability – of the corporate tax code in the US. But it also has generated some angst over Allergan’s future as a stalwart in ophthalmology.

New Enterprise Flies Higher

New Enterprise Associates surprised some by locking down $3.1 billion in new capital during a tight fundraising climate. General partner David Mott and partner Justin Klein share the firm’s investment approach.

Table

View full table

Topics

Tags:
Medical Device
Latest Headlines

Snapshot: August Highlights

Execs On The Move: August 2023

Insitro’s Daphne Koller On The Marriage Of Biology And Machine Learning At The Company’s Heart

Boehringer’s Innovation Strategy Does Not Avoid Areas With Heavy Competition

See All
UsernamePublicRestriction

Register

IV004346

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By